Antitumor activity of CDA-II, a urinary preparation, on human multiple myeloma cell lines via the mitochondrial pathway

Molecular Medicine Reports

Volumn 9, Issue 3, 2014, Pages 1025-1031

  Yang, Min ^a   Huang, Jian ^a   Ma, Qiu Ling ^a   Xu, Gai Xiang ^a   Jin, Jie ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antitumor activity; Cell differentiation agent II; Mitochondrial pathway; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CASPASE INHIBITORS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MULTIPLE MYELOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NF-KAPPA B; OLIGOPEPTIDES; PEPTIDES; PHENYLACETATES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTOR RELA; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84893824099     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1911     Document Type: Article

References (33)

1. Gregory WM, Richards MA and Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334-342, 1992.
2. Lenhoff S, Hjorth M, Holmberg E, et al: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 95: 7-11, 2000.
3. Attal M, Harousseau JL, Facon T, et al; InterGroupe Francophone du Myélome: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495-2502, 2003.
4. Sonneveld P: Drug resistance in multiple myeloma. Pathol Biol (Paris) 47: 182-187, 1999.
5. Covelli A: Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 10 (Suppl 6): 53-59, 1999.
6. Schwarzenbach H: Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 19: 87-104, 2002.
7. Burzynski SR: Antineoplastons: history of the research (I). Drugs Exp Clin Res 12 (Suppl 1): 1-9, 1986.
8. Badria F, Mabed M, Khafagy W and Abou-Zeid L: Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett 155: 67-70, 2000.
9. Lin WC, Wu YW, Lai TY and Liau MC: Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain. Am J Chin Med 29: 91-99, 2001.
10. Masood R, McGarvey ME, Zheng T, Cai J, Arora N, Smith DL, Sloane N and Gill PS: Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo. Blood 93: 1038-1044, 1999.
11. Yao CJ, Lai GM, Chan CF, Yang YY, Liu FC and Chuang SE: Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med 11: 903-908, 2005.
12. Liau MC, Szopa M, Burzynski B and Burzynski SR: Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exp Clin Res 13 (Suppl 1): 61-70, 1987.
13. Sun JJ, Zhou Xd and Liu YK: Effect of CDA-II on prevention and therapy for metastasis and recurrence of liver cancer in nude mice. Chin J Hepatobiliary Surg 546-551, 2006 (In Chinese).
14. Sun L, Huang Q, Wang A, Lan Q, Du Z and Hu G: cDNA array in the establishment of a gene expression profile associated with differentiation inducing the glioma cells. Zhonghua Zhong Liu Za Zhi 24: 222-225, 2002 (In Chinese).
15. Wang YH and Zheng WI: Effects of uroacitides on proliferation ability of breast cancer cells. Chinese Journal of Clinical Pharmacology and Therapeutics 10: 677-681, 1999 (In Chinese).
16. Lin WC, Liao YC, Liau MC, Lii CK and Sheen LY: Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes. Food Chem Toxicol 44: 546-551, 2006.
17. Chen Z, Jin G, Lin S, Lin X, Gu Y, Zhu Y, Hu C, Zhang Q, Wu L and Shen H: DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation. Biochem Biophys Res Commun 422: 522-526, 2012.
18. Huang J, Yang M, Liu H and Jin J: Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin 29: 951-964, 2008.
19. Fischer U and Schulze-Osthoff K: Apoptosis-based therapies and drug targets. Cell Death Differ 12 (Suppl 1): 942-961, 2005.
20. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL and Andreeff M: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108: 630-637, 2006.
21. Burzynski SR: The present state of antineoplaston research (1). Integr Cancer Ther 3: 47-58, 2004.
22. Hehir KM, Baguisi A, Pennington SE, Bates JM and DiTullio PA: A potential antitumor peptide therapeutic derived from antineoplastic urinary protein. Peptides 25: 543-549, 2004.
23. Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL and Figg WD: Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. J Pharm Sci 96: 1821-1831, 2007.
24. Linder-Stragliotto C, Strander H, Munck-Wikland E and Sten-Linder M: Low levels of endostatin in the urine from patients with malignant disease. Tumour Biol 23: 222-227, 2002.
25. Huang J, Yang M, Liu H and Jin J: CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner. Food Chem Toxicol 47: 40-49, 2009.
26. Zhang B, Gojo I and Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99: 1885-1893, 2002.
27. Tu Y, Renner S, Xu F, et al: BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 58: 256-262, 1998.
28. Bharti AC, Shishodia S, Reuben JM, et al: Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184, 2004.
29. Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R and Amiot M: Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67: 5418-5424, 2007.
30. Han J, Goldstein LA, Gastman BR and Rabinowich H: Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281: 10153-10163, 2006.
31. Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL and Anderson KC: A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 27, 721-731, 2008.
32. Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, Takemura T, Suzuki K and Kitagawa M: IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 81: 824-831, 2006.
33. Spets H, Strömberg T, Georgii-Hemming P, Siljason J, Nilsson K and Jernberg-Wiklund H: Expression of the bcl-2 family of pro-and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol 69: 76-89, 2002.